Menu
Search
|

Menu

Close
X

WAVE Life Sciences Ltd WVE.OQ (NASDAQ Stock Exchange Global Market)

44.13 USD
-- (--)
As of Mar 20
chart
Previous Close 44.13
Open --
Volume --
3m Avg Volume 94,819
Today’s High --
Today’s Low --
52 Week High 56.00
52 Week Low 32.25
Shares Outstanding (mil) 34.19
Market Capitalization (mil) 1,508.90
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.57 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
14
FY17
4
FY16
1
EPS (USD)
FY18
-5.062
FY17
-3.836
FY16
-2.407
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.80
Price to Sales (TTM)
vs sector
104.68
8.99
Price to Book (MRQ)
vs sector
17.73
4.66
Price to Cash Flow (TTM)
vs sector
--
40.60
Total Debt to Equity (MRQ)
vs sector
0.00
17.49
LT Debt to Equity (MRQ)
vs sector
0.00
13.83
Return on Investment (TTM)
vs sector
-89.00
12.11
Return on Equity (TTM)
vs sector
-137.73
13.22

EXECUTIVE LEADERSHIP

Gregory Verdine
Independent Chairman of the Board, Since 2012
Salary: $53,886.00
Bonus: --
Paul Bolno
President, Chief Executive Officer, Director, Since 2013
Salary: $515,300.00
Bonus: --
Keith Regnante
Chief Financial Officer, Since 2016
Salary: $120,000.00
Bonus: --
Christopher Francis
Senior Vice President, Corporate Development, Head of Emerging Areas, Since 2017
Salary: $330,000.00
Bonus: --
Chandra Vargeese
Senior Vice President, Head of Drug Discovery, Since 2014
Salary: $350,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

7 Straits View #12-00,
Marina One East Tower
    018936

Phone:

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. The nucleic acid therapeutics, which the Company is developing are stereopure. A stereopure oligonucleotide includes molecules with atoms arranged in three-dimensional orientations at each linkage. The Company has three programs in Huntington's disease (HD) and Duchenne Muscular Dystrophy (DMD), and three additional development candidates.

SPONSORED STORIES